Mark G. Devlin
Peter MacCallum Cancer Centre
18 Papers
115 Citations
Mark G. Devlin is an academic researcher from Peter MacCallum Cancer Centre. The author has contributed to research in topics: Cancer & Agonist. The author has an hindex of 9, co-authored 15 publications. Previous affiliations of Mark G. Devlin include University of Melbourne & Cooperative Research Centre.
Chat about Author
Papers
Modulation of cannabinoid agonist binding by 5-HT in the rat cerebellum.
TL;DR: A membrane‐delimited cross‐talk between two G protein‐coupled receptors that are co‐localized in certain cells of the central nervous system is supported, and the cannabinoid agonist dependence of the 5‐HT modulatory effect suggests that agonist‐specific conformations of the CB1 receptor may also be important in determining the extent of this cross‐ talk.
55
EGFRvIII-mediated transactivation of receptor tyrosine kinases in glioma: mechanism and therapeutic implications.
Sameer A. Greenall,Sameer A. Greenall,Jacqueline F. Donoghue,M. Van Sinderen,V. Dubljevic,S. Budiman,Mark G. Devlin,Ian P. Street,Ian P. Street,Timothy E. Adams,Terrance Grant Johns +10 more
TL;DR: Simultaneously targeting EGFRvIII and the transactivated RTKs themselves in an intracranial mouse model of glioma resulted in significantly greater survival than with either agent alone, indicating that cotargeting theseRTKs has potent antitumor efficacy and providing a strategy for treating EGFRs-expressing gliomas, which are usually refractory to treatment.
48
LIM kinase inhibition reduces breast cancer growth and invasiveness but systemic inhibition does not reduce metastasis in mice
Rong Li,Judy Doherty,Judy Doherty,Juliana Antonipillai,Sheng Chen,Mark G. Devlin,Mark G. Devlin,Kathryn Visser,Kathryn Visser,Jonathan B. Baell,Jonathan B. Baell,Ian P. Street,Ian P. Street,Ian P. Street,Robin L. Anderson,Robin L. Anderson,Ora Bernard,Ora Bernard +17 more
TL;DR: Surprisingly, metastasis to the liver was increased after administration of the LIMK inhibitor, raising a concern about the use of systemic LIMK inhibitors for the treatment of metastatic breast cancer.
45
Highly fluorescent and HDAC6 selective scriptaid analogues
Cassandra L. Fleming,Anthony Natoli,Jeannette Schreuders,Mark G. Devlin,Prusothman Yoganantharajah,Yann Gibert,Kathryn G. Leslie,Elizabeth J. New,Trent D. Ashton,Frederick M. Pfeffer +9 more
TL;DR: Fluorescent scriptaid analogues with excellent HDAC6 selectivity and potency and whole organism imaging in zebrafish confirmed both the vascular localisation of the new inhibitors and the impact ofHDAC6 inhibition on in vivo development.
23
Discovery of a highly potent, selective, orally bioavailable inhibitor of KAT6A/B histone acetyltransferases with efficacy against KAT6A-high ER+ breast cancer.
Shikhar Sharma,Chi-Yeh Chung,S. Uryu,Jelena D. Petrović,Joan Q. Cao,Amanda Rickard,N. Nady,S.E. Greasley,Eric D. Johnson,O. Brodsky,Showkhin Khan,Hui Wang,Zhenxiong Wang,Yong Zhang,Konstantinos E. Tsaparikos,Lei Chen,Anthony Mazurek,John D. Lapek,Pei-Pei Kung,S. Sutton,Paul F. Richardson,Eric Greenwald,Shin Yamazaki,Rhys Jones,K. Maegley,P. Bingham,Hieu Lam,Alexandra E Stupple,Aileen Kamal,A. Chueh,A. Cuzzupe,B. J. Morrow,B. Ren,Catalina Carrasco-Pozo,Chin Wee Godwin Tan,Dharmesh D. Bhuva,E. Allan,Elliot Surgenor,F. Vaillant,Havva Pehlivanoglu,Hendrik Falk,James R. Whittle,Janet Newman,Joseph Cursons,Judy P. Doherty,K. White,Laura MacPherson,Mark G. Devlin,M. Dennis,M. Hattarki,M. de Silva,M. Camerino,Miriam S. Butler,Olan Dolezal,P. Pilling,R. Foitzik,P. Stupple,H. Rachel Lagiakos,Scott E. Walker,Soroor Hediyeh-Zadeh,S. Nuttall,S. K. Spall,Susan A. Charman,T. Connor,Thomas S. Peat,Vicky M. Avery,Y. E. Bozikis,Yuqing Yang,Ming Zhang,Brendon J. Monahan,Anne K. Voss,Tim Thomas,I. Street,Sarah-Jane Dawson,Mark A. Dawson,Geoffrey J. Lindeman,Melissa J. Davis,Jane E. Visvader,Thomas A Paul +78 more
TL;DR: Researchers identified CTx-648, a potent and selective KAT6A/B inhibitor, which shows anti-tumor activity in ER+ breast cancer by inhibiting H3K23Ac and downregulating estrogen signaling, cell cycle, and stem cell pathways, offering a potential therapeutic strategy.
22